Nov. 9 at 10:51 PM
$ADVM No incorrect. The lowest possible buyout price is 3.56 meaning your maximum loss is less than 15% whereas maximum gain 300% +|- I can’t imagine anyone going short with this in mind. The market has been in decline for over a week and ADVM has shown its strength on the upside. Absolutely a buy unless you hate money then go short on it.
The agreed-upon buyout structure provides for a potential total value of up to
$12.47 per share:
Upfront Cash:
$3.56 per share, payable upon the deal's closing (expected in Q4 2025).
Contingent Value Right (CVR): One CVR per share, potentially worth up to an additional
$8.91, based on two specific milestones:
$1.78 per CVR if Ixo-vec (Adverum's lead gene therapy candidate) receives U.S. regulatory approval within seven years of the deal closing.
$7.13 per CVR if Ixo-vec achieves annual global net sales exceeding
$1 billion within ten years of closing.
